Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir

Magda Opsomer,Dessislava Dimitrova,Johan Verspeelt,Amy Purrington,Abdul Mehbob,Scott Chavers,Helen Pai,Simon Vanveggel,D. Luo,Kimberley Brown,Christiane Moecklinghoff,Richard E. Nettles,Katia Boven

Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir

2018

Magda Opsomer
Dessislava Dimitrova
Johan Verspeelt
Amy Purrington
Abdul Mehbob
Scott Chavers
Helen Pai
Simon Vanveggel
D. Luo
Kimberley Brown
Christiane Moecklinghoff
Richard E. Nettles
Katia Boven

Introduction We evaluated cardiovascular disease (CVD) risk associated with darunavir treatment and examined the demographic/clinical characteristics of darunavir users based on data from Janssen-sponsored clinical trials, post-marketing pharmacovigilance databases, and administrative claims databases.

Keywords:

Clinical trial
Pharmacology
Medicine
Physical therapy
Darunavir
Disease
Pharmacovigilance
Population
Ritonavir
sudden death
Internal medicine
Epidemiology
Atazanavir

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations